GBC-HPVAC

Based on the observation that certain components of the human gut microbiome confer protection against various diseases, HpVac has developed HpVac-13, a molecule harnessing the beneficial potential of some microbial species. The compound is a patented, recombinant version of a naturally occurring immunomodulatory protein and demonstrates strong epidemiological evidence of protecting humans against asthma and other allergic diseases.

Also known as: GBC-HpVac SA

Primary location: Geneva Switzerland